Table 1. PB clonoSEQ MRD results Subject... | American Society of Hematology

Table 1.

PB clonoSEQ MRD results

Subject	Age at diagnosis, y	MIPI risk	Best response	PFS, mo	MRD assay time point
Subject	Age at diagnosis, y	MIPI risk	Best response	PFS, mo	Time on study, mo	Maintenance regimen	MRD result	MRD interpretation
1	51	Low	CR	69+	51	LR	<10⁻⁶	Undetectable
2	55	Intermediate	CR	65+	49	LR	<10⁻⁶	Undetectable
3	53	Low	CR	65+	51	LR	<10⁻⁶	Undetectable
4	65	Intermediate	CR	62+	42	None*	<10⁻⁶	Undetectable
5	66	High	CR	62+	62	R	3.0 × 10⁻⁶	Detectable
6	73	High	PR	61+	46	R	1.2 × 10⁻⁵	Detectable
7	56	Intermediate	CR	56+	43	None*	<10⁻⁶	Undetectable
8	80	High	CR	53+	35	R	<10⁻⁶	Undetectable
9	60	Low	CR	45+	42	R	<10⁻⁶	Undetectable
10	82	High	CR	46+	46	R	<10⁻⁶	Undetectable

Subject	Age at diagnosis, y	MIPI risk	Best response	PFS, mo	MRD assay time point
Subject	Age at diagnosis, y	MIPI risk	Best response	PFS, mo	Time on study, mo	Maintenance regimen	MRD result	MRD interpretation
1	51	Low	CR	69+	51	LR	<10⁻⁶	Undetectable
2	55	Intermediate	CR	65+	49	LR	<10⁻⁶	Undetectable
3	53	Low	CR	65+	51	LR	<10⁻⁶	Undetectable
4	65	Intermediate	CR	62+	42	None*	<10⁻⁶	Undetectable
5	66	High	CR	62+	62	R	3.0 × 10⁻⁶	Detectable
6	73	High	PR	61+	46	R	1.2 × 10⁻⁵	Detectable
7	56	Intermediate	CR	56+	43	None*	<10⁻⁶	Undetectable
8	80	High	CR	53+	35	R	<10⁻⁶	Undetectable
9	60	Low	CR	45+	42	R	<10⁻⁶	Undetectable
10	82	High	CR	46+	46	R	<10⁻⁶	Undetectable

R, rituximab.

Two subjects opted to discontinue study treatment after 3 years.